lundi 21 octobre 2019

Onco Actu du 21 octobre 2019


3.1.1 PRÉVENTION - TABAC - E-CIGS



Erdogan says he will never allow vaping, will block e-cigarettes in Turkey [Reuters]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



International alliance sets bold research ambition to detect the (almost) undetectable [Cancer Research UK]










Cancer research: Scientists seek clues to how disease 'is born' [BBC News]











£55m Anglo-US research alliance to boost early cancer detection rates [The Guardian]











4.12 BIOPSIES LIQUIDES



Colon Cancer Recurrence Clues Identified in Post-Treatment ctDNA Detection [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Cervical Cancer Exomes Point to Potentially Targetable HER, PIK3CA Pathway Changes [Genome Web]











NIH funds new All of Us Research Program genome center to test advanced sequencing tools [NIH]











New diagnostic method finds aggressive tumours [Karolinska Institutet]











4.9 DÉP., DIAG. & PRONO. - SEIN



Massive marketing muscle pushes 3D mammograms, despite no evidence they save more lives, investigation shows [USA Today]










5. TRAITEMENTS



Jeffrey Aronson: When I Use a Word . . . Explaining drug shortages [BMJ]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma [Roche]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer [Xconomy]











Armed with Langer tech and $50M, Verseau hails new checkpoint drugs unleashing macrophages against cancer [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma [Merck]











EMA Recommends Extension of Indications for Pembrolizumab [ESMO]











5.2 PHARMA



J&J reels after FDA finds 'sub-trace' levels of asbestos in its baby powder [Fierce Pharma]











Johnson & Johnson Recalls Baby Powder Over Asbestos Worry [NY Times]











Top ALK expert and cancer drug researcher Alice Shaw bids adieu to academia, hello to Novartis [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



A change of the guard for the world’s biggest cancer companies [Vantage]











5.2.6 PHARMA - BIOTECH



Mirati sets date for closely watched clinical KRAS readout [Fierce Biotech]











Mirati data to test whether biotech can challenge Amgen in KRAS quest [Fierce Pharma]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma [Genmab]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019 [EMA]










6. LUTTE CONTRE LES CANCERS



Dr. Bernard Fisher, Who Revolutionized Breast Cancer Treatment, Dies at 101 [NY Times]










6.1 OBSERVATION



Current and ex smokers may lower lung cancer risk with exercise [Reuters]











6.8 COMMUNICATION



Neglecting Major Health Problems and Broadcasting Minor, Uncertain Issues in Lifestyle Science [JAMA]










6.9 CONTROVERSES



Precision Medicine Targets Wallets Better Than Disease [Tincture]











Understanding Precision Medicine And AI Within The Life Cycle Of Technology Revolutions [Forbes]